---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-324768"
form_type: "8-K"
ticker: "VOR"
cik: "0001817229"
company_name: "Vor Biopharma Inc."
filed_at: "2025-12-18T23:59:59+00:00"
generated_at: "2026-05-16T12:46:33.957570+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Vor Bio raises $150M in private placement; appoints two new directors

## Summary
- Private placement of 13.9M shares at $10.81 for gross proceeds of ~$150M.
- New/existing investors include RA Capital, Forbion, Frazier Life Sciences, Caligan, Logos, Venrock.
- Proceeds to advance telitacicept Phase 3 trials for myasthenia gravis and Sjögren's disease.
- Director Sarah Reed resigned; Andrew Levin (RA Capital) and Wouter Joustra (Forbion) appointed.
- Levin and Joustra receive standard director fees and option grants of 3,000 shares each.

## SEC filing metadata
- accession: 0001193125-25-324768
- form_type: 8-K
- ticker: VOR
- cik: 0001817229
- company_name: Vor Biopharma Inc.
- filed_at: 2025-12-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817229/000119312525324768/0001193125-25-324768-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817229/000119312525324768/vor-20251215.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-324768
- JSON: https://secwatch.observer/filing/0001193125-25-324768.json
- Plain text: https://secwatch.observer/filing/0001193125-25-324768.txt

## Key facts
- Equity Issuances
  Vor Biopharma Inc. issued 13,876,032 shares of common stock to institutional and accredited healthcare specialist investors for $10.81 per share, gross proceeds approximately $150 million.
  - Security: common stock
  - Shares: 13,876,032 shares
  - Purchaser: institutional and accredited healthcare specialist investors
  - Consideration: $10.81 per share, gross proceeds approximately $150 million
  source text: Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a securities purchase agreement to sell 13,876,032 shares of its common stock at a price of $10.81 per share to a select group of institutional and accredited healthcare specialist investors in a private placement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1817229/000119312525324768/0001193125-25-324768-index.htm
- Material Agreements
  Vor Biopharma Inc. entered into Securities Purchase Agreement with certain investors valued at 13,876,032 shares of common stock at $10.81 per share for gross proceeds of approximately $150.0 mil (effective 2025-12-15).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain investors
  - Value: 13,876,032 shares of common stock at $10.81 per share for gross proceeds of approximately $150.0 mil
  - Effective: 2025-12-15
  source text: On December 15, 2025, Vor Biopharma Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (the “Investors”) pursuant to which the Company, in a private placement, agreed to issue and sell to the Investors an aggregate of 13,876,032 shares (the “Shares”) of the Company’s common stock, at a price per Share of $10.81, for gross proceeds of approximately $150.0 million (the “Private Placement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1817229/000119312525324768/0001193125-25-324768-index.htm
- Material Agreements
  Vor Biopharma Inc. entered into Registration Rights Agreement with certain investors valued at Company obligated to file S-3 registration statement within 45 days of closing and use best efforts (effective 2025-12-15).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain investors
  - Value: Company obligated to file S-3 registration statement within 45 days of closing and use best efforts
  - Effective: 2025-12-15
  source text: In connection with the Private Placement, the Company also entered into a Registration Rights Agreement, dated December 15, 2025 (the “Registration Rights Agreement”), with the Investors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1817229/000119312525324768/0001193125-25-324768-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.